Treatment Outcomes for up to 2 Years in Patients Aged Less Than 12 Years with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis: Real-World Data From PEDISTAD

Amy S. Paller,Marjolein de Bruin-Weller,Danielle Marcoux,Eulalia Baselga,Vania Oliveira de Carvalho,Ledit R. F. Ardusso,Mirna Toledo-Bahena,Rajan Gupta,Marius Ardeleanu,Annie Zhang

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用 0|浏览4

暂无评分

摘要

Background: In phase-3 studies, dupilumab significantly improved disease severity in patients with moderate-to-severe atopic dermatitis (AD); however, less is known about the impact of systemic treatments on children in real-world treatment settings.

查看译文

关键词

treatment outcomes,moderate-to-severe,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要